AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Above 50-Day Moving Average – What’s Next?

AB Corporate Bond ETF (NASDAQ:EYEG)’s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $35.56 and traded as high as $35.63. AB Corporate Bond ETF shares last traded at $35.67, with a volume of 15 shares trading hands.

AB Corporate Bond ETF Stock Up 0.6%

The company has a market capitalization of $28.54 million, a P/E ratio of -21.23 and a beta of 0.23. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $35.56 and its 200 day moving average is $35.85.

AB Corporate Bond ETF Increases Dividend

The firm also recently announced a monthly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Wednesday, April 1st were paid a dividend of $0.1433 per share. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date of this dividend was Wednesday, April 1st. AB Corporate Bond ETF’s payout ratio is -104.17%.

Institutional Trading of AB Corporate Bond ETF

A number of hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of AB Corporate Bond ETF in the 2nd quarter worth approximately $232,000. Wealth Enhancement Advisory Services LLC boosted its holdings in AB Corporate Bond ETF by 6.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 119,017 shares of the specialty pharmaceutical company’s stock worth $4,301,000 after acquiring an additional 6,988 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in AB Corporate Bond ETF in the fourth quarter worth $34,000. 64.16% of the stock is owned by institutional investors.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.